logo

Can-Fite Biopharma Ltd. (CANF)



Trade CANF now with
  Date
  Headline
1/7/2020 8:24:34 AM Can-Fite BioPharma To Present Data From Phase II Liver Cancer Study With Namodenoson
1/3/2020 7:05:11 AM Can-Fite BioPharma Says New Data From Hadassah Medical Center Lab Show Namodenoson Induces Weight Loss
12/26/2019 7:04:37 AM Golan Bitton Univo Pharma CEO Elected To Can-Fite Board
12/9/2019 8:17:40 AM Can-Fite Completes 50% Patient Enrollment In Phase III Psoriasis Trial
11/29/2019 7:03:42 AM Can-Fite BioPharma 9-month Net Loss $7.84 Mln Vs $3.14 Mln Last Year
11/19/2019 7:07:26 AM Can-Fite BioPharma Secures Patents For Its Sexual Dysfunction Drug
11/11/2019 7:03:55 AM Can-Fite Granted U.S. Patent For Piclidenoson In The Treatment Of Osteoarthritis
10/15/2019 6:34:58 AM Can-Fite Completes Patient Enrollment In Phase II NASH Study Of Namodenoson
8/29/2019 7:06:08 AM Can-Fite H1 Net Loss $4.9 Mln Vs Net Loss $3.0 Mln Last Year
8/1/2019 8:54:22 AM Can-Fite Signs Distribution Deal With Kyongbo Pharm To Distribute Piclidenoson
5/6/2019 7:05:38 AM Can-Fite Conducts Preparatory Work For Pivotal Phase III Study Of Namodenoson
3/28/2019 7:17:18 AM Can-Fite BioPharma FY Revenues $3.8 Mln, Increase Of $3.0 Mln Or 384%
3/26/2019 7:10:05 AM Can-Fite Announces Phase II Advanced Liver Cancer Top-Line Results For Orphan/Fast Track Drug Namodenoson
2/4/2019 7:11:41 AM Can-Fite Receives Notice Of Allowance From U.S. Patent And Trademark Office For Osteoarthritis Drug
1/24/2019 7:35:10 AM Can-Fite BioPharma Says Achieved Significant Number Of Milestones In 2018
1/8/2019 8:08:14 AM Can-Fite Says Pre-Clinical Data Positions Namodenoson As An Anti-Obesity Agent
11/30/2018 7:05:26 AM Amended: Can-Fite 9-month Net Loss $3.1 Mln Vs Net Loss $4.7 Mln Last Year
9/4/2018 7:05:53 AM Can-Fite BioPharma Provides Update On Phase II Clinical Trial Of Namodenoson
8/31/2018 7:02:30 AM Can-Fite 6-month Loss $3.0 Mln Vs Loss $3.5 Mln Last Year
  
 
>